EGFR and metastatic colorectal cancer: Although numerous studies have reported conflicting results regarding molecular biomarkers, the KRAS gene currently stands as the most validated and clinically applicable marker for guiding targeted therapy with epidermal growth factor receptor (EGFR) inhibitors in patients with metastatic colorectal cancer [121].